meRfi®-GM
Prostate cancer
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Metastatic castration-resistant prostate cancers have enriched DNA repair gene defects (DRDs) that can be possibly treated by inhibiting PARP proteins
Smith et al. 2022 The Lancet Oncology 23: 362-373
Prostate cancer is the fifth leading cause of cancer-related death among men with the majority of deaths linked to metastatic disease.
Advanced prostate cancer is characterized by a continuum of states, distinguished by the presence or absence of metastasis and sensitivity or resistance to androgen deprivation therapy (ADT).
Prostate can…
References (Sources)
- Apalutamide for the treatment of metastatic castration-sensitive prostate cancer
- Degradation of Androgen Receptor through Small Molecules for Prostate Cancer
- Emerging cell cycle inhibitors for treating metastatic castration resistant prostate cancer
- Immune-based therapies for metastatic prostate cancer: an update
- Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas
- Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Pts With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
- Prostate Cancer